ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
ESMO 2023 – sabestomig has it all to do in TIM-3
Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.
ESMO 2023 – butterflies for J&J
Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.
ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
